MGI, a company committed to being a world-leading life science  innovator, today announced a partnership with Nalagenetics (NALA) to co-develop low  coverage whole genome sequencing for risk prediction and pharmacogenomics through  optimizing Next Generation Sequencing (NGS) workflow based on MGI’s sequencing devices  and products*. 

The collaboration aims to use NALA’ Clinical Decision Support, a software medical device, to  be able to analyze whole genome sequencing data sets generated by MGI’s DNBSEQTM  sequencing platform*, and generate clinical-grade reports for pharmacogenomics and  polygenic risk scores. Although NGS has been known to be an effective way to capture a large  amount of genomic information to guide and tailor clinical management and treatment,1 NGS  workflows are complicated and not trivial to adopt in clinical settings. NALA is dedicated to help  implement clinical genetic testing in Southeast Asia with strong expertise in pharmacogenetics,  , assay development, and AI-linked genetics analysis for pharmacological phenotypes and risk  prediction.  

“Pharmacogenetic testing adoption in Southeast Asia is still low despite interest from  customers, as Next Generation Sequencing is a multi-step process that can be complex and  difficult to implement in existing settings. The partnership with Nalagenetics will merge both our  expertise and bring about a simplified Next Generation Sequencing workflow with automation,  sequencing primer design and process QC within current healthcare framework,” said Dr. Roy  Tan, General Manager, MGI Asia Pacific.  

“We see more and more hospitals adopting sequencing for personalization of medicine in  oncology, cardiovascular conditions, and others. One of the biggest challenges is  recommending follow up action that makes sense for the local market, for example list of  alternative therapies and screening procedures that lead to cost-effectiveness. We are glad to  work with MGI to co-develop products and offer services to answer local needs,” said Levana  Sani, CEO of Nalagenetics.